Novel Anti-Alzheimer Therapeutics Discovery and Development

Alzheimer disease (AD) is uniquely characterized amyloid dysregulation (Amyloid Aggregate > Clear). The emerging paradigm: Target Aβ Oligomers

Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases

Developing anti Aβ, Tau and α-Syn bispecific and multi- therapeutic antibody and Fc fusion proteins candidates

The several Anti- Aβ therapeutic Bispecific antibody candidates have been selected

The multi- targets therapeutic candidates for AD have been generated

The candidates of enhancing the BBB infiltration therapeutics for AD have been selected

AI supporting antibody drug R&D for brain disease

AI-driven optimization of anti-amyloid antibody to minimize plasma binding

AI-driven optimization of anti-TfR1 nanobody antibody to improve antibody cross BBB

generated anti-amyloid anft-TfR1 BsAb have showed tens folds antibody in brain tissue in vivo evaluation

The selected lead candidates ready for license-out, co-development, and strategic pharmaceutical partnerships.

For more information regarding our products in development, feel free to reach out to us.